The peptide regulatory landscape in 2026 is in active flux. After the FDA placed 19 popular peptides in Category 2 in late 2023, HHS Secretary RFK Jr. announced in February 2026 that In the Pipeline: Top Drug Candidates for FDA Approval in 2024 Researchers examine cancer drug guidelines and FDA approvals New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then, Sermorelin: Benefits, FDA Status & Safety in 2025 Healthon Potential FDA Peptide Reclassification 2026 What It Means for Patients Beverly Hills Rejuvenation Center